Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-01-17

Study Completion Date

2025-12-04

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background:

Sometimes prostate cancer comes back after a person's prostate is removed. In this case, radiation is a common treatment. Radiation kills prostate cancer cells. It can be very effective. It is usually given in short doses almost every day for 6 or 7 weeks. Researchers want to see if a shorter schedule can be as effective. They want to see if that causes the same or fewer side effects. Usually, radiation is used to treat the entire area where the prostate was before surgery. In some patients, an area of tumor can be seen on scans. Researchers are also trying to see if they can give less dose to the area usually treated with radiation if the full dose is given to the tumor seen on scans.

Objective:

To find the shortest radiation schedule that people can tolerate without strong side effects.

Eligibility:

People at least 18 years old who have had a prostatectomy and will get radiation.

Design:

Participants will be screened with:

* Medical history
* Physical exam
* Blood and urine tests
* Scan that uses a small amount of radiation to make a picture of the body
* Scan that uses a magnetic field to make an image of the body
* Participants will provide documents that confirm their diagnosis.
* Participants may have a scan of the abdomen and pelvis.

Before they start treatment, participants will have another physical exam and blood tests.

Participants will get radiation each day Monday through Friday. Treatment may last 2, 3, or 4 weeks.

Participants may provide a tissue sample from a previous procedure for research.

Participants will answer questions about their general well-being and function.

About 4-5 weeks after they finish radiation treatment, participants will have a follow-up visit. They will be examined and give a blood sample. They will have 6 follow-up visits for the next 2 years.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase III Intensity Radiotherapy Dose Escalation for Prostate Cancer Using Hypofractionation

NCT00667888

Prostate Cancer

UNKNOWN PHASE3

Phase I/II Hypofractionated Radiotherapy for Prostate Cancer

NCT00214097

Prostate Cancer

COMPLETED PHASE1/PHASE2

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

NCT03987386

Stage I Prostate Cancer AJCC v8 Stage II Prostate Cancer AJCC v8 Stage III Prostate Cancer AJCC v8 +1 more

ACTIVE_NOT_RECRUITING PHASE3

Hypofractionated Radiotherapy (55 Gy/16 Fractions/4 Weeks) for Localized Prostate Cancer

NCT00129025

Prostate Cancer

COMPLETED PHASE1/PHASE2

Hypofractionated Stereotactic Body Radiation Therapy for Patients With Prostate Cancer That Was Removed by Surgery

NCT02446366

Stage II Prostate Adenocarcinoma Stage IIB Prostate Cancer Stage III Prostate Adenocarcinoma

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BACKGROUND:

Prostate cancer that recurs after prostatectomy (rising prostate-specific antigen (PSA) with no evidence of metastatic disease is often treated with radiation to the entire prostate bed to a dose of 66-72 Gray (Gy) over 6-7 weeks. This treatment can provide PSA control in approximately 75% of patients but may have associated genitourinary and gastrointestinal toxicity due to irradiation of the rectum, small bowel, and bladder. Imaging of prostate cancer has improved to the extent that recurrent disease is often identified in the prostate bed or in other pelvic sites. The current standard is to irradiate the entire prostate bed to the total dose. This trial will test the tolerability of accelerated treatment designed to yield a similar rate of late toxicity. In addition, in patients with visible tumor, it will test the feasibility of delivering a lower dose to the prostate bed and an integrated boost (simultaneous) to the visible tumor to allow a higher dose to visible tumor than can be delivered with standard approaches.

OBJECTIVE:

\- Define the maximum tolerated dose (MTD) hypofractionation of image guided, focally dose escalated post-prostatectomy radiation.

ELIGIBILITY:

* PSA recurrence after prostatectomy or indications for adjuvant radiation after prostatectomy.
* No evidence of distant metastases of prostate cancer (pelvic lymph nodes are allowed).
* Age greater than or equal to 18 years old
* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1

DESIGN:

This is a Phase I trial of hypofractionated focal dose escalation with reduced dose prostate bed irradiation using image and pathologic guidance. The prostate bed will be treated with hypofractionated radiation and areas in the prostate bed or pelvis shown to have tumor on biopsy or with advanced imaging studies will be treated with an integrated boost to visible tumor. The treatment duration will be decreased sequentially in three Dose Level groups. Quality of life and functional outcomes such as urine, bowel, and erectile function will be assessed with questionnaires. A maximum of 48 patients will be enrolled.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cancer Of Prostate Prostate Neoplasms Prostate Cancer Neoplasms of Prostate Prostatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Arm 1/Prostate Bed with Integrated Boost

Prostate bed with integrated boost.

Group Type EXPERIMENTAL

Prostate bed with integrated boost

Intervention Type RADIATION

Radiation will be delivered at an escalated dose to areas of recurrent prostate cancer identified on imaging and a reduced dose will be delivered to the entire prostate bed.

Whole Body Bone Scan

Intervention Type DIAGNOSTIC_TEST

At screening, if required by clinician.

18F-NaF PET Imaging

Intervention Type DIAGNOSTIC_TEST

At screening, if required by clinician.

CT

Intervention Type DIAGNOSTIC_TEST

Computed tomography of the abdomen and pelvis if clinically indicated at screening, with oral and intravenous contrast.

mpMRI

Intervention Type DIAGNOSTIC_TEST

mpMRI of the prostate bed at screening and 6 month follow up.

ADT

Intervention Type DRUG

After enrollment if clinically indicated (i.e., anti-androgen, gonadotropin releasing hormone agonist, or combination of both).

Arm 2/Prostate Bed Irradiation Only

Prostate bed irradiation only.

Group Type EXPERIMENTAL

Prostate bed irradiation only

Intervention Type RADIATION

Radiation will be delivered to the prostate bed only.

Whole Body Bone Scan

Intervention Type DIAGNOSTIC_TEST

At screening, if required by clinician.

18F-NaF PET Imaging

Intervention Type DIAGNOSTIC_TEST

At screening, if required by clinician.

CT

Intervention Type DIAGNOSTIC_TEST

Computed tomography of the abdomen and pelvis if clinically indicated at screening, with oral and intravenous contrast.

mpMRI

Intervention Type DIAGNOSTIC_TEST

mpMRI of the prostate bed at screening and 6 month follow up.

ADT

Intervention Type DRUG

After enrollment if clinically indicated (i.e., anti-androgen, gonadotropin releasing hormone agonist, or combination of both).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Prostate bed with integrated boost

Radiation will be delivered at an escalated dose to areas of recurrent prostate cancer identified on imaging and a reduced dose will be delivered to the entire prostate bed.

Intervention Type RADIATION

Prostate bed irradiation only

Radiation will be delivered to the prostate bed only.

Intervention Type RADIATION

Whole Body Bone Scan

At screening, if required by clinician.

Intervention Type DIAGNOSTIC_TEST

18F-NaF PET Imaging

At screening, if required by clinician.

Intervention Type DIAGNOSTIC_TEST

CT

Computed tomography of the abdomen and pelvis if clinically indicated at screening, with oral and intravenous contrast.

Intervention Type DIAGNOSTIC_TEST

mpMRI

mpMRI of the prostate bed at screening and 6 month follow up.

Intervention Type DIAGNOSTIC_TEST

ADT

After enrollment if clinically indicated (i.e., anti-androgen, gonadotropin releasing hormone agonist, or combination of both).

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Fluorine 18-sodium fluoride positron emission tomography Computed tomography Multiparametric magnetic resonance imaging androgen deprivation therapy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients must have histologically or cytologically confirmed adenocarcinoma of the prostate.
* Indications for post-prostatectomy radiation exist:

* Disease progression (detectable prostate-specific antigen (PSA) on two measurements obtained at least one month apart) or
* indications for adjuvant radiation exist (if undetectable PSA): pathologic T3, T4, N+ disease or positive margins (within 1 year of prostatectomy).
* Age greater than or equal to 18 years.
* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 1 (Karnofsky greater than or equal to 60)
* Ability of subject to understand and the willingness to sign a written informed consent document.
* Radiation is teratogenic; thus, men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation and up to 120 days after the last radiation. Should a woman become pregnant or suspect she is pregnant while her partner is participating in this study, she should inform her treating physician immediately.
* Human immunodeficiency virus (HIV) positive patients are included if CD4+ (cytotoxic T cells) T-cell count \> 200 cells/uL; on stable antiretroviral therapy for \> 1 year with HIV viral load \<200 copies/mL, and no history of opportunistic infections in \> 1 year.

Exclusion Criteria

* Patients who are receiving any other investigational agents concurrently.
* Documented metastases of prostate cancer outside of the pelvis (pelvic lymph nodes are allowed only if within the prostate bed region).
* History of radiation that would overlap with the intended treatment to the prostate bed.
* Known contraindications to radiation such as inflammatory bowel disease, active systemic lupus or scleroderma, or radiation hypersensitivity syndrome (Ataxia Telangiectasia or Fanconi's Anemia)
* Subjects with any coexisting medical or psychiatric condition which, in the opinion of the Investigator likely to interfere with study procedures and/or results.
* Medically indicated use of known radiosensitizing drugs (such as protease inhibitors)

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No